Bellapium HA Dermal Filler with Lidocaine 0.3%: Features, Benefits, Types, Injection Guide & Product Information
Meta Title: Bellapium HA Dermal Filler with Lidocaine 0.3% | Klipport
Meta Description: Discover Bellapium HA Dermal Filler with 24 mg/ml hyaluronic acid and 0.3% lidocaine. Explore its key features, S/M/L variants, applications, injection guide and maintenance information.
Suggested URL Slug: bellapium-ha-dermal-filler-lidocaine-klipport
Bellapium HA Dermal Filler with Lidocaine 0.3% – Detailed Product Guide
In modern aesthetic treatments, dermal fillers are widely used for facial contouring and volume enhancement. Bellapium™ HA Dermal Filler with Lidocaine 0.3% is a hyaluronic-acid-based dermal filler presented by DASAN Pharmaceutical Co., Ltd. The product brochure describes Bellapium as a monophasic, soft and uniform filler designed to provide easy molding, smooth injection and natural-looking results.
For clinics and aesthetic professionals looking for a versatile HA dermal filler system, Bellapium offers three product variants—Bellapium S, Bellapium M and Bellapium L—with different molecule sizes, needle specifications, indications and stated maintenance periods.
At Klipport, we provide information about aesthetic and cosmetic treatment products to help clinics and professionals understand their features and applications.
What Is Bellapium HA Dermal Filler?
Bellapium is an HA (hyaluronic acid) dermal filler containing 0.3% lidocaine. According to the manufacturer brochure, each variant has an HA concentration of 24 mg/ml, while the addition of 0.3% lidocaine is intended to support patient comfort during injection.
The Bellapium range is based on different molecular sizes:
- Bellapium S – Small Molecule
- Bellapium M – Medium Molecule
- Bellapium L – Large Molecule
The brochure associates these variants with different facial areas and stated maintenance periods.
Key Highlights of Bellapium Dermal Filler
1. Monophasic, Soft & Uniform Formulation
One of the major features highlighted in the Bellapium brochure is its monophasic, soft and uniform formulation.
The manufacturer states that this characteristic offers:
- Easy molding
- Smooth handling
- Natural-looking results
- Consistent injection characteristics
The brochure specifically contrasts the monophasic Bellapium structure with a biphasic filler presentation.
2. 24 mg/ml Hyaluronic Acid
Bellapium is formulated with a stated 24 mg/ml concentration of hyaluronic acid across the S, M and L variants.
Hyaluronic acid is the primary filler material highlighted in the product documentation and forms the basis of Bellapium’s volume-enhancing application.
3. 0.3% Lidocaine
Bellapium contains 0.3% lidocaine, according to the product brochure.
The product’s marketing message describes this combination as:
“Volume UP, Pain DOWN.”
This makes the presence of lidocaine one of the key product features highlighted by the manufacturer.
4. Smooth and Continuous Injection Feel
The brochure states that Bellapium can be injected with a consistent extrusion force because of its homogeneous particle size achieved through a fine grinding process.
This is an important product characteristic for aesthetic professionals because consistent extrusion can contribute to controlled product delivery during a procedure.
The brochure also includes extrusion-force comparison graphs for Bellapium variants on page 3, illustrating the manufacturer’s testing presentation.
5. Long-Lasting Volume Effect
Bellapium’s product literature highlights a long-lasting superior volume effect.
According to the brochure, the relatively high concentration of hyaluronic acid is intended to minimize exposure to degradation enzymes and free radicals in the human body, thereby slowing decomposition.
The product information provides different stated maintenance periods depending on the Bellapium variant and treatment area.
6. Purification Process
The Bellapium brochure includes a purification diagram showing hyaluronic acid and BDDE residue before and after purification. It states that the purification process is designed to minimize BDDE residue.
This purification information is presented as part of the product’s quality and safety features.
7. Manufactured in an ISO-13485-Approved Facility
The brochure states that Bellapium is produced in an ISO-13485-approved facility and presents this as part of its quality and safety positioning.
Bellapium S, M & L – Understanding the Three Variants
Bellapium is available in three variants designed around different molecular sizes.
| Variant | Molecule Size | HA Concentration | Lidocaine | Needle Size | Stated Maintenance Period |
|---|---|---|---|---|---|
| Bellapium S | Small Molecule | 24 mg/ml | 0.3% | 30G | 4–6 months |
| Bellapium M | Medium Molecule | 24 mg/ml | 0.3% | 27G | 6–12 months |
| Bellapium L | Large Molecule | 24 mg/ml | 0.3% | 25G | 12 months |
These specifications are taken directly from the product information section of the manufacturer’s brochure.
Bellapium S – Small Molecule HA Filler
Bellapium S is the small-molecule version of the Bellapium range.
According to the product information:
- Molecule: Small
- HA concentration: 24 mg/ml
- Lidocaine: 0.3%
- Needle: 30G
- Stated maintenance period: 4–6 months
The brochure lists eyelids and lip contour among its indicated areas.
Eyelid Application
The manufacturer’s injection guide lists:
- Dosage: 0.1–0.2 cc per injection
- Depth: 2–3 mm
- Interval: 0.05–2 cm
Lip Contour Application
The brochure lists:
- Dosage: 0.05–0.5 cc per injection
- Depth: 2–3 mm
- Interval: 0.05–2 cm
Bellapium M – Medium Molecule HA Filler
Bellapium M uses the medium-molecule formulation.
Its stated specifications include:
- Molecule: Medium
- HA concentration: 24 mg/ml
- Lidocaine: 0.3%
- Needle: 27G
- Stated maintenance period: 6–12 months
The manufacturer lists several facial areas for this variant, including the forehead, double chin, nose and cheekbone.
Forehead
The brochure lists:
- Dosage: 0.1–0.5 cc per injection
- Depth: 2–3 mm
- Interval: 0.05–2 cm
Double Chin
The stated guide lists:
- Dosage: 0.1–0.5 cc per injection
- Depth: 3 mm
- Interval: 0.05–2 cm
Nose
The brochure lists:
- Dosage: 0.1–0.3 cc per injection
- Depth: 1.5–3 mm
- Interval: 0.05–2 cm
Cheekbone
The brochure lists:
- Dosage: 0.2–0.5 cc per injection
- Depth: 3 mm
- Interval: 0.05–2 cm
Bellapium L – Large Molecule HA Filler
Bellapium L is the large-molecule formulation.
Its product specifications are:
- Molecule: Large
- HA concentration: 24 mg/ml
- Lidocaine: 0.3%
- Needle: 25G
- Stated maintenance period: 12 months
The manufacturer’s guide lists smile lines and side cheekbones among the indicated areas.
Smile Lines
The brochure specifies:
- Dosage: 0.2–0.5 cc per injection
- Depth: 1–3 mm
- Interval: 0.05–2 cm
Side Cheekbones
The brochure specifies:
- Dosage: 0.1–0.5 cc per injection
- Depth: 2–3 mm
- Interval: 0.05–2 cm
Bellapium Injection Guide
The manufacturer’s brochure provides a facial injection guide showing different treatment zones across the face. The guide covers areas including:
- Eyelids
- Lip contour
- Forehead
- Double chin
- Nose
- Cheekbone
- Smile lines
- Side cheekbones
The brochure also provides recommended needle sizes, dosage ranges, depths and intervals for each Bellapium variant. These details should be interpreted as manufacturer-provided product information for trained medical professionals, not as a substitute for clinical judgment, local regulations, product labeling or professional training.
Maintenance Period of Bellapium
The brochure provides the following stated maintenance periods:
- Bellapium S: 4–6 months
- Bellapium M: 6–12 months
- Bellapium L: 12 months
The brochure further states that treatment can be repeated every 4–6 months and recommends more than three treatments for the best effects, while noting that the maintenance period should align with the product and target area.
Actual treatment schedules should be determined by an appropriately qualified healthcare professional based on the individual patient and treatment plan.
Why Choose Bellapium HA Dermal Filler?
Bellapium combines several features into a three-product system:
✔ 24 mg/ml Hyaluronic Acid
A consistent HA concentration is specified across the S, M and L variants.
✔ 0.3% Lidocaine
Each variant contains 0.3% lidocaine according to the manufacturer’s product information.
✔ Three Molecular Sizes
Small, medium and large molecule options allow professionals to select the product variant according to the manufacturer’s indicated treatment areas.
✔ Monophasic Structure
The brochure highlights a soft and uniform monophasic formulation for easy molding and natural-looking results.
✔ Consistent Extrusion
The manufacturer attributes the continuous injection feel to homogeneous particle size produced through fine grinding.
✔ Purification
The product literature highlights a purification process intended to minimize BDDE residue.
✔ Quality-Focused Manufacturing
The brochure states that the product is produced in an ISO-13485-approved facility.
Bellapium vs. Different Facial Treatment Areas
One of the useful aspects of the Bellapium system is that the manufacturer provides different variants for different facial indications.
Bellapium S is presented for finer areas such as the eyelids and lip contour.
Bellapium M is presented for areas including the forehead, double chin, nose and cheekbone.
Bellapium L is presented for smile lines and side cheekbones.
This multi-variant approach allows aesthetic professionals to work with a product range rather than relying on a single formulation for every treatment area.
Product Quality & Manufacturing
Bellapium is identified in the brochure as a product of DASAN Pharmaceutical Co., Ltd., Seoul, Korea. The brochure provides the manufacturer’s Seoul address and contact details.
The product literature emphasizes quality and safety through its stated manufacturing facility and purification process.
Bellapium HA Dermal Filler – Key Specifications at a Glance
| Feature | Bellapium |
|---|---|
| Product Type | HA Dermal Filler |
| Hyaluronic Acid | 24 mg/ml |
| Lidocaine | 0.3% |
| Formulation | Monophasic, soft & uniform |
| Variants | S, M & L |
| Molecular Sizes | Small, Medium & Large |
| Needle Sizes | 30G / 27G / 25G |
| Stated Maintenance | 4–6 / 6–12 / 12 months |
| Manufacturer | DASAN Pharmaceutical Co., Ltd. |
| Country | Korea |
| Facility | ISO-13485-approved facility, according to brochure |
Frequently Asked Questions About Bellapium
What is Bellapium?
Bellapium is a hyaluronic-acid dermal filler containing 24 mg/ml HA and 0.3% lidocaine, available in S, M and L formulations.
How many Bellapium variants are available?
The Bellapium range contains three variants: Bellapium S, Bellapium M and Bellapium L.
What is the difference between Bellapium S, M and L?
The variants differ in molecular size, recommended needle size, indicated facial areas and stated maintenance period.
Does Bellapium contain lidocaine?
Yes. The product brochure states that Bellapium contains 0.3% lidocaine.
What is the HA concentration?
The stated hyaluronic acid concentration is 24 mg/ml.
How long does Bellapium last?
The brochure states maintenance periods of 4–6 months for S, 6–12 months for M and 12 months for L. Results and maintenance requirements can vary according to the treatment area and individual circumstances.
Final Thoughts
Bellapium HA Dermal Filler with Lidocaine 0.3% is a three-variant hyaluronic-acid filler system designed around different molecular sizes and facial treatment applications. Its key product characteristics include a monophasic soft and uniform formulation, 24 mg/ml HA concentration, 0.3% lidocaine, homogeneous particle size and a manufacturer-stated purification process intended to minimize BDDE residue.
With Bellapium S, M and L, the product range provides different options for the facial areas specified in the manufacturer’s injection guide.
For clinics and aesthetic professionals seeking detailed product information, Klipport.com can serve as a source for information about Bellapium and other aesthetic products.
Important: This article is based on the supplied Bellapium manufacturer brochure. The dosage, injection depth, needle size and treatment information above should be used only by appropriately trained and licensed medical professionals and must be checked against the current official product labeling and applicable local requirements before clinical use. The brochure itself does not provide enough information to independently establish regulatory approval or clinical suitability in every country.